InxMed (Shanghai) Co., Ltd. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14
What changed in the last 30 days
6 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 5 with minor changes only.
- Notable: FAK Inhibitor · Advanced Solid Tumors Primary completion pushed from Feb 28, 2027 to Sep 30, 2027
- Minor: IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer Enrollment closed, study ongoing
- Minor: IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC Enrollment closed, study ongoing
- Minor: IN10018 Combination Therapy in Treatment-naïve ES-SCLC Enrollment closed, study ongoing
- Minor: IN10018+ Standard Chemotherapy (+KN046) · Advanced Pancreatic Cancer Enrollment closed, study ongoing
- Minor: IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD · Platinum-resistant Recurrent Ovarian Cancer Enrollment closed, study ongoing
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 1 | |
| Phase 1/2 | 6 | |
| Phase 2 | 1 | |
| Phase 3 | 1 |
Disease areas by active trials
Lung Cancer (3) · Non-Small Cell Lung Cancer (NSCLC) (2) · Ovarian Cancer (2) · Pancreatic Cancer (2) · Small Cell Lung Cancer (1)
Get alerts when InxMed (Shanghai) Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.